BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3127886)

  • 1. Potential approaches for therapeutic intervention of thrombosis by fibrinolytic agents.
    Collen D
    Semin Thromb Hemost; 1988 Jan; 14(1):95-9. PubMed ID: 3127886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin-specific thrombolytic agents.
    Collen D
    Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic agents: mechanisms of activity and pharmacology.
    Lijnen HR; Collen D
    Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
    Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
    Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.